Previously, the ACHIEVE-1 study evaluated orforglipron monotherapy in people with early type 2 diabetes uncontrolled with lifestyle intervention, and demonstrated a 12 mmol/mol (1.1%) greater HbA 1c reduction and a 5.9% greater body weight reduction than placebo (Rosenstock et al, 2025)
To be able to have one medication that can have two benefits is pretty magnificent, says Umashanker
Microorganisms, 3(4), 641666
Self-administration means fewer weight management center visits Benefit Body Mounjaro comes in an easy-to-use pen formulation
The underlying condition is sequenced first per ICD-10-CM guidelines
Clinical Evidence for Metformin-Semaglutide Combination Therapy Multiple studies have examined patients on dual metformin and GLP-1 therapy, showing additive benefits for weight loss and blood sugar reduction